Zynerba Pharmaceuticals Top Management
ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
Zynerba Pharmaceuticals employs about 25 people. The company is managed by 5 executives with a total tenure of roughly 18 years, averaging almost 3.0 years of service per executive, having 5.0 employees per reported executive. Evaluation of Zynerba Pharmaceuticals' management performance can provide insight into the firm performance.
James Fickenscher President CFO, Vice President - Corporate Development |
Terri Sebree President President |
Zynerba |
Zynerba Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4511) % which means that it has lost $0.4511 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8713) %, meaning that it created substantial loss on money invested by shareholders. Zynerba Pharmaceuticals' management efficiency ratios could be used to measure how well Zynerba Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Zynerba Pharmaceuticals Workforce Comparison
Zynerba Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 6,060. Zynerba Pharmaceuticals adds roughly 25.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Zynerba Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zynerba Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zynerba Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zynerba Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kenneth Moch over a year ago Disposition pursuant to a tender of shares in a change of control transaction by Kenneth Moch of Zynerba Pharmaceuticals | ||
Brian Rosenberger over a year ago Acquisition by Brian Rosenberger of 22200 shares of Zynerba Pharmaceuticals subject to Rule 16b-3 | ||
Kenneth Moch over a year ago Acquisition by Kenneth Moch of 47824 shares of Zynerba Pharmaceuticals subject to Rule 16b-3 | ||
Parker Albert P over a year ago Sale by Parker Albert P of 3173 shares of Zynerba Pharmaceuticals | ||
Parker Albert P over a year ago Acquisition by Parker Albert P of 18864 shares of Zynerba Pharmaceuticals subject to Rule 16b-3 | ||
Parker Albert P over a year ago Acquisition by Parker Albert P of 17631 shares of Zynerba Pharmaceuticals subject to Rule 16b-3 |
Zynerba Pharmaceuticals Notable Stakeholders
A Zynerba Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zynerba Pharmaceuticals often face trade-offs trying to please all of them. Zynerba Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zynerba Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
James Fickenscher | CFO, Vice President - Corporate Development | Profile | |
Terri Sebree | President | Profile | |
Albert II | Chief Sec | Profile | |
Armando MBA | Chairman CEO | Profile | |
Joseph Apostolico | VP HR | Profile |
About Zynerba Pharmaceuticals Management Performance
The success or failure of an entity such as Zynerba Pharmaceuticals often depends on how effective the management is. Zynerba Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zynerba management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zynerba management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Zynerba Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
Please note, the presentation of Zynerba Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zynerba Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zynerba Pharmaceuticals' management manipulating its earnings.
Zynerba Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Zynerba Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zynerba Pharmaceuticals within its industry.Zynerba Pharmaceuticals Manpower Efficiency
Return on Zynerba Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.4M | |
Net Loss Per Executive | 7M | |
Working Capital Per Employee | 1.8M | |
Working Capital Per Executive | 9.1M |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |